Prime Medicine Elects Directors at Annual Meeting

Prime Medicine, Inc. ( (PRME) ) has shared an update.

On June 4, 2025, Prime Medicine, Inc. held its annual stockholders meeting virtually, where a quorum was established with over 98 million shares represented. Stockholders elected Thomas Cahill and Robert Nelsen as Class III Directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025, indicating continued confidence in the company’s leadership and financial oversight.

The most recent analyst rating on (PRME) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.

Spark’s Take on PRME Stock

According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.

Prime Medicine, Inc. faces significant financial hurdles with ongoing losses and dependency on external funding. While recent technical indicators show potential for recovery, the stock remains under pressure. The promising preclinical results offer a positive long-term outlook, but the current valuation and financial performance weigh heavily on the overall score.

To see Spark’s full report on PRME stock, click here.

More about Prime Medicine, Inc.

Prime Medicine, Inc. operates in the biotechnology industry, focusing on developing innovative gene editing technologies and therapies.

Average Trading Volume: 1,844,285

Technical Sentiment Signal: Sell

Current Market Cap: $174.6M

For a thorough assessment of PRME stock, go to TipRanks’ Stock Analysis page.